Spruce Biosciences
Late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders, including congenital adrenal hyperplasia (CAH). Publicly traded on NASDAQ (SPRB).
Notes
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is publicly traded on NASDAQ under the ticker symbol SPRB and is headquartered in Daly City, California.
The company's lead program, tildacerfont, is being developed for the treatment of classic congenital adrenal hyperplasia (CAH), a rare genetic condition that affects the adrenal glands' ability to produce cortisol. Tildacerfont is a selective CRF1 receptor antagonist designed to reduce excess androgen production while maintaining cortisol levels.
Team
- Javier Szwarcberg, M.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/javiersz
- Stuart Tross, Ph.D. - Chief Scientific Officer
- Liz Woo - Chief Financial Officer
Additional Research Findings
- NASDAQ: SPRB (publicly traded)
- Investor: 5AM Ventures
- Focus on rare endocrine disorders
- Lead program: Tildacerfont for congenital adrenal hyperplasia (CAH)
- CRF1 receptor antagonist mechanism
- Daly City, California headquarters
- Founded in 2016
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| 5AM Ventures | Menlo Park, USA | biotech-focused | seedseries-a+1 | 8 |
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |